These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26701356)

  • 1. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
    Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M
    J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
    Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S
    J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.
    Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
    Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
    Argiriadi MA; Goedken ER; Banach D; Borhani DW; Burchat A; Dixon RW; Marcotte D; Overmeyer G; Pivorunas V; Sadhukhan R; Sousa S; Moore NS; Tomlinson M; Voss J; Wang L; Wishart N; Woller K; Talanian RV
    BMC Struct Biol; 2012 Sep; 12():22. PubMed ID: 22995073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead identification of novel and selective TYK2 inhibitors.
    Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
    Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
    Norman P
    Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of
    Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
    Fensome A; Ambler CM; Arnold E; Banker ME; Brown MF; Chrencik J; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gopalsamy A; Hayward MM; Hegen M; Hollingshead BD; Jussif J; Knafels JD; Limburg DC; Lin D; Lin TH; Pierce BS; Saiah E; Sharma R; Symanowicz PT; Telliez JB; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X; Zhang L
    J Med Chem; 2018 Oct; 61(19):8597-8612. PubMed ID: 30113844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
    Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
    Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors.
    Sasaki Y; Tokuhara H; Ohba Y; Okabe A; Nakayama M; Nakagawa H; Skene R; Hoffman I; Zou H; Yoshida M
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126963. PubMed ID: 31980341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.